Results 141 to 150 of about 2,348 (179)
Sonidegib for the treatment of advanced basal cell carcinoma [PDF]
Expert Opinion on Pharmacotherapy, 2016 Advanced and metastatic basal cell carcinomas (BCCs) are rare but still present a severe medical problem. These tumors are often disfiguring and impact the quality of life by pain or bleeding. Based on discovery of the hedgehog (Hh) signaling pathway and its role in the pathogenesis of BCCs, smoothened (SMO) inhibitors have been developed with ...
Egle Ramelyte, Reinhard Dummer
exaly +5 more sources
Future Oncology, 2018 Sonidegib, a hedgehog pathway inhibitor, was approved by the US FDA for the treatment of locally advanced basal cell carcinoma which cannot be readily treated with surgery or radiotherapy.
Sirunya Silapunt, Heng-Huan Lee
exaly +2 more sources
Gorlin Syndrome-Associated Basal Cell Carcinomas Treated with Vismodegib or Sonidegib: A Retrospective Study [PDF]
CancersNevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome (GS), is a genetic disorder characterized by the development of multiple cutaneous BCCs due to mutations in the hedgehog signaling pathway. The use of hedgehog pathway inhibitors&
Giulia Murgia +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
FDA Approval Summary: Sonidegib—Letter
Clinical Cancer Research, 2017We read with interest the FDA approval summary for sonidegib, an inhibitor of the Hedgehog signaling pathway and smoothened receptors, for patients with locally advanced basal cell carcinoma ([1][1]).
Bishal, Gyawali, Yuichi, Ando
openaire +2 more sources
FDA Approval Summary: Sonidegib—Response
Clinical Cancer Research, 2017Race and ethnicity are important considerations during drug development, with differential effects in drug exposure, efficacy, and safety across racial groups observed for some drugs. Gyawali and Ando ([1][1]) suggest that the recommended dose of 200 mg once daily for sonidegib may not ...
Stacy S, Shord +5 more
openaire +2 more sources
Sonidegib: First Global Approval
Drugs, 2015Sonidegib (Odomzo™) is an orally bioavailable, small molecule, Smoothened (SMO) receptor antagonist that is being developed by Novartis for the treatment of cancer. SMO is a G protein-coupled receptor-like molecule that is essential for the actions of the Hedgehog family of secreted proteins, which play a critical role in the development and ...
openaire +2 more sources
Sonidegib: A Review in Locally Advanced Basal Cell Carcinoma
Targeted Oncology, 2016Sonidegib (Odomzo®), an oral smoothened (SMO) antagonist, is indicated for the treatment of adults with locally advanced basal cell carcinoma (laBCC) who are not candidates for surgery or radiation therapy, or adults with recurrent laBCC following surgery or radiation therapy.
Celeste B, Burness, Lesley J, Scott
openaire +2 more sources
Sonidegib phosphate: new approval for basal cell carcinoma
Drugs of Today, 2016Basal cell carcinoma (BCC), although mostly locally confined, is the most common cancer. Most BCCs harbor inactivating mutations in the membrane receptor/gene Ptch, thereby activating the Hedgehog signaling pathway (Hh) via the essential signaling molecule Smoothened (SMO).
openaire +2 more sources